Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Exclusion Criteria

• •male breast cancer or inflammatory breast cancer.
• •Patients who have other malignant tumors or have contracted malignant tumors other than breast cancer in the past 5 years, except for basal cell carcinoma of the skin or flat cell carcinoma and carcinoma in situ of the cervix that have been adequately treated and controlled.
• •Accompanying other anti-tumor treatments or participating in other clinical trials.
• •Serious diseases that will affect the patient's compliance or put the patient at risk.
• •Major surgical procedures performed within 4 weeks prior to the commencement of study treatment or anticipated major surgical procedures during the course of the study.
• •Patients who have used ADC drugs at present or before this study.
• •History of allergic reactions or contraindications to use of any drug ingredient in this study.
• •Patients with chronic diarrhea and intestinal obstruction, as well as other diseases that affect drug administration and absorption.
• •Patients who have clinical cardiac symptoms or diseases that are not well controlled, such as: heart failure above NYHA 2; unstable angina; myocardial infarction occurred within one year; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.
• •Dementia, intellectual abnormality, or any mental illness that interferes with the understanding of informed consent.